

## REMARKS

The specification and Abstract have been amended to correct typographical errors. The Title has been amended to conform to the subject matter presented for examination. In response to the outstanding Restriction Requirement, Applicant has canceled claims 1-24, and 26-39, amended claim 25, and added claims 40-54. Accordingly, claims 25 and 40-54 are presented for examination.

These amendments and additional claims do not add new matter. Specifically, the amendment of claim 25 is supported by the Specification, for example, at page 9, lines 1-45 (which identifies examples of subjects, including humans, in need of treatment by the claimed invention), page 12, line 11 (which teaches using a therapeutic dose of elastin), and page 10, line 12, page 16, lines 13-15 and page 14, lines 18-24 (which teaches increasing the diameter of a biological conduit (e.g. artery or vein) and the choice of a therapeutic dose for this purpose).

Support for claim 40 can be found in the Specification, for example, at page 12, line 11.

Support for claim 41 can be found in the Specification, for example, at page 13, line 15 – page 14, line 16.

Support for claim 42 can be found in the Specification, for example, at original claim 9.

Support for claim 43 can be found in the Specification, for example, at page 7, lines 23-24 and page 13, lines 22-25.

Support for claim 44 can be found in the Specification, for example, at original claim 1.

Support for claims 45 and 47 can be found in the Specification, for example, at original claim 10.

Support for claim 46 can be found in the Specification, for example, at page 17, lines 2-4.

Support for claims 48-50 can be found in the Specification, for example, at page 9, lines 5-8.

Support for claim 51 can be found in the Specification, for example, at page 7, lines 23-24 and page 13, lines 22-25.

Support for claims 52-54 can be found in the Specification, for example, at page 16, line 27 – page 17, line 11.

CONCLUSION

Applicant respectfully requests examination of the pending claims. Applicant believes that no fees for additional claims are required. In the event that any fee is required, the Director is hereby authorized to charge any required fees to Fried, Frank, Harris, Shriver & Jacobson LLP Deposit Account No. 06-0920.

Respectfully submitted,

Date: September 30, 2005

 40,286  
Stephen S. Rabinowitz (Reg. No.)  
**FRIED, FRANK, HARRIS, SHRIVER**  
**& JACOBSON LLP**  
One New York Plaza  
New York, New York 10004  
(212) 859-8973

517996.1